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Abstract
H. pylori persists in the human stomach over decades and promotes several adverse clinical sequelae including gastritis,
peptic ulcers and gastric cancer that are linked to the induction and subsequent evasion of chronic gastric inflammation.
Emerging evidence indicates that H. pylori infection may also protect against asthma and some other immune-mediated
conditions through regulatory T cell effects outside the stomach. To characterize the complexity of the CD4+ T cell response
generated during H. pylori infection, computational methods were previously used to generate a panel of 90 predicted
epitopes conserved among H. pylori genomes that broadly cover HLA Class II diversity for maximum population coverage.
Here, these sequences were tested individually for their ability to induce in vitro responses in peripheral blood mononuclear
cells by interferon-c ELISpot assay. The average number of spot-forming cells/million PBMCs was significantly elevated in H.
pylori-infected subjects over uninfected persons. Ten of the 90 peptides stimulated IFN-c secretion in the H. pylori-infected
group only, whereas two out of the 90 peptides elicited a detectable IFN-c response in the H. pylori-uninfected subjects but
no response in the H. pylori-infected group. Cytokine ELISA measurements performed using in vitro PBMC culture
supernatants demonstrated significantly higher levels of TNF-a, IL-2, IL-4, IL-6, IL-10, and TGF-b1 in the H. pylori-infected
subjects, whereas IL-17A expression was not related to the subjects H. pylori-infection status. Our results indicate that the
human T cell responses to these 90 peptides are generally increased in actively H. pylori-infected, compared with H. pylori-
naı¨ve, subjects. This information will improve understanding of the complex immune response to H. pylori, aiding rational
epitope-driven vaccine design as well as helping identify other H. pylori epitopes with potentially immunoregulatory effects.
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Introduction
Helicobacter pylori (H. pylori) is a NIAID emerging pathogen [1]
that infects the gastric mucosa of half the human population,
leading to chronic gastric inflammation in all and clinically
important adverse outcomes in a sizable minority. While most
infections with this gram-negative bacterium are not associated
with symptoms, gastric or duodenal ulcers ultimately develop in
approximately 10% of colonized individuals, with gastric adeno-
carcinoma or mucosal-associated lymphoid tissue lymphoma
occurring in about 1%, decades after the initial infection. H. pylori
infection is unevenly distributed, being most prevalent in resource-
poor countries (in the range of 70–90%) and in as few as 10% or
less of some Western populations [2]. Stomach cancer, which is
largely attributable to H. pylori [3], is responsible for 10,900 deaths
per year in the US [4] and about 738,000 deaths annually
worldwide [5]. H. pylori infection, usually acquired in childhood,
leads to the recruitment of immune and inflammatory cells to the
stomach. [2] The pathogenesis of gastritis, peptic ulcer disease and
gastric cancer associated with H. pylori is subsequently linked with
the intensity and quality of the innate and adaptive chronic
immune responses in the gastric mucosa. [6,7]
Although infection with H. pylori is pathogenic in a subset of the
colonized population, ‘‘beneficial’’ effects of persistent H. pylori
infection have been proposed, due to a consistent inverse
relationship between the loss of gastric H. pylori colonization and
the emergence of certain conditions of increasing prevalence in
fully industrialized nations, including some characterized by
unrestrained inflammation outside the stomach. These conditions
include childhood-onset asthma, inflammatory bowel disease,
eosinophilic esophagitis and even esophageal adenocarcinoma.
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[8,9,10,11,12] Experimental evidence in mice suggests that the
acquisition of H. pylori infection early in life may reprogram
mucosal and systemic immunity in the direction of increased
regulatory T cell function and decreased inflammation outside the
stomach [13,14].
Because interactions between H. pylori and the immune system
are implicated in both the pathogenesis of H. pylori-associated
diseases and ‘‘protection’’ against certain extra-gastric conditions,
it is important to understand precisely how H. pylori interacts with
elements of the host immune system. We have used computational
methods to identify a core H. pylori genome, comprising 676 open
reading frames from seven genetically and phenotypically diverse
H. pylori strains [15]. The core genome served as a source for
identification of HLA Class II epitopes with broad coverage of
circulating H. pylori strains. Complementing H. pylori coverage, we
used immunoinformatic tools to identify 90 T-cell epitopes that
broadly cover HLA Class II diversity for maximum population
coverage (see Table S1). HLA binding studies validated
computational predictions with 79% accuracy for a panel of six
HLA Class II alleles, representing .90% of the global human
population [15]. Here, we report functional studies testing the
human T cell responses to each of these 90 peptides by interferon-
c ELISpot assay, since this is a widely used screening method to
measure effector functions of low-frequency antigen-specific T cell
populations to class II epitopes in human PBMCs [16] including to
a putative H. pylori vaccine candidate. [17]
This is the first large-scale discovery study for HLA class II-
restricted H. pylori immune epitopes. Prior studies focused on HLA
class II epitopes found in the urease beta subunit and in
neuraminyllactose-binding hemagglutinin. [17,18] Using an un-
biased approach we have probed the entire H. pylori proteome to
identify T cell targets within conserved consensus and potentially
immunogenic peptide sequences. Our results indicate that these
sequences generally elicited significantly higher in vitro responses
in those patients already infected by H. pylori in comparison with
H. pylori-naı¨ve subjects. This information will improve under-
standing of the complex immune response to H. pylori and should
aid rational epitope-driven vaccine design.
Results
H. pylori peptides predicted by immunoinformatic
screening to be T-cell epitopes are recognized
preferentially by H. pylori-infected patients PBMC’s in
interferon-c ELISpot assays
To test the immunogenicity of a panel of 90 peptides predicted
by immunoinformatic screening to contain conserved H. pylori
epitopes, human IFN-c ELISpot assays were performed in 96-well
plates pre-coated with human IFN-c specific monoclonal capture
antibodies. PBMC (2.56105/well) isolated from H. pylori-infected
and uninfected patients were incubated with 90 H. pylori antigen-
specific peptides individually at a final concentration of 10 mg/ml
for 24 hours. Representative ELISpot images from three H. pylori-
infected and three H. pylori-uninfected patients are shown in
Figure 1A, demonstrating the increased number of IFN-c
secreting cells in H. pylori-infected subjects.
In general, the majority of the 90 peptides elicited a higher IFN-
c ELISpot response (in terms of number of spot forming cells) in
H. pylori-infected subjects than in the uninfected subjects
(Figure 1B). Using as a threshold for positivity the 2x background
vehicle value, the mean (6 SEM) number of SFC per million
PBMCs across all subjects and across all peptides was 10.861.5 in
the H. pylori-infected versus 1.960.2 in the uninfected cases (***
P,0.0001). The individual responses of each subject to each
peptide tested are listed in Table S2.
Ten of the 90 peptides stimulated IFN-c secretion in the H.
pylori-infected group only, whereas two out of the 90 peptides
elicited a weak IFN-c response in the H. pylori-uninfected subjects
but no response in the H. pylori-infected group.
The specificity of the response was verified by blocking class II
HLA presentation with a pan- HLA class II antibody. The 9 most
frequently recognized peptides from the 90 peptide panel were
evaluated in the 8 most highly responsive H. pylori infected subjects
in the presence or absence of the blocking antibody. The results
indicate that the blocking antibody suppressed the mean IFN-c
ELISpot response in all patients for each of the peptides tested
(Figure 1C), and overall by an average of 81.6%, P,0.01.
H. pylori genome-derived peptides elicited strong in vitro
Th1/Treg, but not Th17A cytokine expression by PBMCs
from H. pylori-infected humans, when compared to H.
pylori-uninfected group
To further evaluate T cell responses to each of these peptides,
ELISpot well supernatants from a subset of five patients in each
group (H. pylori-infected and uninfected) were assayed by a
multiplex cytokine bead array. The five patients per group were
selected based on their being the most responsive to the peptide
panel in ELISpot analysis. All the data were expressed as mean 6
SEM after subtracting background values (DMSO vehicle
controls). Individual peptide responses for all five patients in each
group illustrate elevated Th1 and Treg cytokine responses in H.
pylori-infected patients (Figure 2A). Overall, averaging the data
for all 90 peptides, there was significantly higher expression of
TNF-a (368633.5 versus 40620.5 pg/ml, ***P,0.0001), IL-2
(11.2163.9 versus 1.160.1 pg/ml), IL-6 (6314635.1 versus
21516418.9 pg/ml, ***P,0.0001) and IL-10 (36.562.8 versus
360.9 pg/ml, ***P,0.0001) in the supernatants from H. pylori-
infected subjects compared to H. pylori-uninfected subjects,
respectively. (Figure 2B). Furthermore, there was a statistically
significant correlation between TNF-a expression and IFN-c
ELISpot results (P,0.0001, R2 = 0.2217). IL-4 levels were
extremely low in both groups of patients and IL-17A levels were
not significantly different between the H. pylori-infected versus
uninfected subjects (9.860.9 versus 10.661.4 pg/ml). Individual
level results per patient per peptide are listed in Table S3.
TGF-beta 1 (TGF-b1) protein expression was analyzed in the
same 5 supernatants from each group by ELISA (for individual
level results per patient per peptide see Table S3). As shown in
Figure 2C, TGF-b1 expression in PBMC supernatants from
peptide-stimulated wells was higher in the H. pylori-infected
subjects than the uninfected subjects (202.869.9 versus
144.067.3 pg/ml, ***P,0001), which is consistent with the
IL-10 profile above and the immunosuppressive role these
cytokines play in maintaining H. pylori persistence and mediating
H. pylori-specific immunomodulation [19]. However, the difference
between groups for TGF-b1 was relatively small, and because
there is an acid activation step used to measure TGF-b1 by
ELISA, the levels may not reflect accurately differences in the
biologically active protein (reviewed in [20]).
Cytokine correlations with epitope mapping predictions
The relationship between computational predictions of H. pylori
HLA Class II ligands made by the EpiMatrix epitope mapping
algorithm [15] and their recognition by PBMCs as experimentally
tested here was determined. Because HLA types are diverse in the
human population, the predictive profile of the epitope peptide
Human Immune Response to H. pylori Epitopes
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Figure 1. In vitro PBMC IFN-c secretion measured by ELISpot in response to 90 individual H. pylori genome-derived peptides. A)
Representative human IFN-c ELISpot images. Representative images of IFN-c ELISpot wells stimulated by three different epitopes (4534,
4553 and 4568). Data are from three patients in each group. The number of spots per well is stated by the side of each well image. H. pylori genome-
derived peptides are recognized preferentially by PBMCs from H. pylori-infected patients. Stimulation with Phorbol 12-myristate 13-acetate (PMA)
Human Immune Response to H. pylori Epitopes
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sequences was initially determined for each individual subject
according to the subject’s HLA type [21]. The predictive profile is
described by an individual T cell epitope measure (iTEM) value
that is calculated per sequence as an estimate of the likelihood that
it would stimulate an immune response, as described in the
Methods. iTEM values ranged from the lowest value for a single
prediction in the top 5th percentile of EpiMatrix prediction for a
single DR allele, 1.65, up to 12.21, representing a sequence with
multiple hits for two different DR alleles of a subject.
(20 ng/ml) and ionomycin (1 mM) provide the positive control, while 0.05% dimethyl sulfoxide (DMSO) treated PBMCs served as a negative control in
this assay. Hp+: H. pylori-infected patients, Hp-: H. pylori-uninfected patients. B) ELISpot results for each peptide sorted from highest spot
forming cell number to lowest in the H. pylori-infected subjects. PBMCs extracted from 15 H. pylori-infected and 15 H. pylori-uninfected
patients were co-cultured with 90 individual H. pylori peptides (10 mg/ml) in anti-human IFN-c pre-coated 96-well ELISpot plates for 24 hours. IFN-c
spot forming cells (SFC) were counted by an S5 automated immunospot analyzer. Each column represents the average of SFC per million PBMCs over
2x background for each peptide in H. pylori-infected subjects + SEM (Hp+, black column, top panel) and H. pylori-uninfected subjects (Hp-, white
columns, lower panel), respectively. P,0.0001, H. pylori-infected versus uninfected group overall. C) Inhibition of peptide-stimulated IFN-c
production by Pan-HLA II blocking antibody. PBMCs from 8 H. pylori-infected subjects were co-cultured with the peptides shown in the
absence (black columns) or presence (white columns) of Pan-HLA II blocking antibody. Data expressed as the average (+SEM) of SFC per million
PBMCs over 2x background with mean % inhibition due to the blocking antibody listed below each peptide number. * P,0.05, absence vs presence
of blocking antibody.
doi:10.1371/journal.pone.0094974.g001
Figure 2. In vitro PBMC cytokine profiling in ELISpot well supernatants in response to 90 individual H. pylori genome-derived
peptides. Supernatants from ELISpot assay cultures were assayed for multiple cytokine concentrations by cytometric beads array (CBA) and TGF-b1
concentration by ELISA. (A) Individual peptide responses for individual patients are shown in heatmap format for TNF-a (Th1) and IL-10 (Treg)
cytokines. The heat map rows represent individual patients (5 H. pylori positive and 5 H. pylori negative) and the columns represent responses to
individual peptides. Graphical analysis of the dataset was performed using PermutMatrix 1.9.3 [51]. For comparison of different cytokines, expression
levels were normalized. (B, C) Columns represent average values (6 SEM) of 90 individual peptide-stimulated cytokine secretion minus background
values in H. pylori-infected patients (Hp+, white column) and H. pylori uninfected patients (Hp-, black column). All data are shown as specific cytokine
concentration in pg/ml of supernatant (mean 6 SEM). * P,0.05; *** P,0.0001; NS: no significant difference; N= 5.
doi:10.1371/journal.pone.0094974.g002
Human Immune Response to H. pylori Epitopes
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Correlations were then made between iTEM values and the
Th1 and Treg cytokine data for all predicted epitopes across the
H. pylori-infected and uninfected cohorts (Table S4). Th1 and
Treg cytokines were selected for analysis for their importance in H.
pylori immunity and the statistically significant distinction between
H. pylori-infected and uninfected subject responses to the predicted
epitopes observed for these cytokines. A minimal iTEM value that
predicts cytokine stimulation with statistical significance was
determined, as described in the Methods, for H. pylori-infected
subjects, the population expected to respond to the peptides. For
IFN-c measured by ELISpot assay, the iTEM value is 5.02
(N = 15); for TNF-a, 5.10, and IL-10, 5.36, as measured by the
CBA assay (N = 5). The iTEM algorithm predicts with high
sensitivity (.87% for all cytokines), as the proportion of true
positives to false negatives is high, whereas specificity is low
because of high numbers of false positives (Figure 3). False
positives arise, in part, because of error in predictions, and, in part,
due to (i) low frequencies of antigen-specific T cells, which are to
be expected in subjects who were likely initially infected with H.
pylori decades before this study, (ii) leukocytes taken from outside
the primary site of infection, and due to (iii) the type of cytokine
measurements performed in this study where cells were not
cultured to expand low frequency clones. We note that the
proportion of false positives is noticeably lower for TNF-a and IL-
10 than IFN-c, even for the IFN-c dataset from the subset of five
subjects used to measure TNF-a and IL-10 (data not shown). This
may be related to the difference in defining a positive response in
the assays used to measure these cytokines: whereas bulk cytokine
secretion above background is generally accepted to be significant
in the CBA assay, in the ELISpot assay cytokine-producing cells
exceeding twice background levels are considered significant.
Alternatively, iTEM may be a better predictor of amount of
cytokine production than numbers of cytokine-producing cells, but
that could be reliably determined only by comparing the two
assays for production of the same cytokine, which was not feasible
in this study. Finally, we note that when the iTEM values above
are applied to the respective cytokine datasets collected from H.
pylori-negative subjects, it is apparent that the proportion of true
positive and negative predictions in infected subjects is noticeably
greater than in uninfected, as expected.
Discussion
We observed antigen-specific functional differences between the
T cell repertoires of H. pylori-positive and -negative subjects for a
set of 90 immunoinformatic-predicted T-cell epitopes from seven
genetically diverse H. pylori strains. This study expands the number
of known H. pylori epitopes that stimulate human T cell responses.
A search of the Immune Epitope Database reveals only 11
peptides from three different antigens discovered until now
[17,18,22,23] The present study uncovered 90 new epitopes
derived from 81 unique antigens.
Many H. pylori gene products have been tested for vaccine
development in preclinical studies over the last three decades since
H. pylori was recognized. However, the only vaccine candidates
that have been evaluated in human subjects are whole formalin-
inactivated H. pylori, [24] urease subunits A and B (heterodimers
necessary for urease’s catalytic activity), [25,26,27] HP0231
(function currently unknown) [26] and a trivalent vaccine
comprising recombinant CagA (cytotoxin-associated gene A),
VacA (vacuolating cytotoxin A) and NAP (neutrophil activating
protein). [28] Of the 81 proteins represented by our 90 peptide
panel, most are related to metabolic and intracellular signaling
pathways [15] and none has been previously suggested for
consideration as an H. pylori vaccine candidate or been identified
as a correlate of H. pylori immunity. Interestingly, among the
predicted epitopes in the current study three are related to H.
pylori’s flagellum (flagellum-specific ATP synthases, flagellar
biosynthesis protein FlhA and flagellar basal body L-ring protein),
and the urease accessory protein ureH that functions with three
other urease accessory proteins (urease E, F and G) to regulate the
insertion of nickel to activate the urease A/B complex. [27]
Furthermore, among the 90 computationally-selected peptides in
our panel, 5 are related to H. pylori’s cag pathogenicity island, a 32-
gene cluster associated with H. pylori virulence (ulcer disease and
cancer) that encodes a type IV secretion system capable of
inserting bacterial products (such as the CagA protein) into host
epithelial cells. [29] CagA has been extensively studied as a
putative bacterial oncoprotein and as an immunodominant and
long-lived marker of past and current H. pylori infection [29]. Two
of the predicted epitopes in our panel were in Cag6 (also known as
CagZ or HP0526 in the H. pylori strain 26695 nomenclature), a
high-abundance protein essential for CagA translocation, [30] and
others were in Cag11 ( = CagU = HP0531, an inner membrane
protein essential for secretion apparatus function [31]), Cag17
( = CagN = HP0538, a poorly characterized periplasmic compo-
nent of the type IV secretion system [30] and HP1451 (an
inhibitor of HP0525 ( = Cag alpha) which is an inner membrane
ATPase essential for CagA translocation. [32] Thus several
peptide sequences discovered by our informatics screen relate to
proteins known to be essential for H. pylori virulence, including
flagellar function (motility), urease activity (acid tolerance) and the
cag pathogenicity island (type IV secretion).
The fact that any one specific peptide only elicits a response in
on average 20.2 % of H. pylori-infected subjects suggests that a
multi-epitope approach for H. pylori vaccine development will be
needed when using a computational approach to epitope
prediction.
Importantly, the results also suggest that extragastric T cells
with H. pylori specificities form an antigen-specific memory T cell
repertoire in the periphery in H. pylori-positive humans. Cytokine
responses are (i) observed only when stimulated by peptides, (ii) are
mediated by HLA class II presentation as anti-Class II antibody
blocks peptide-stimulated IFN-c responses and (iii) are detected in
brief overnight cultures following blood collection. Surprisingly,
similar, though weaker and lower frequency, responses in the H.
pylori-naı¨ve population were detected. As a primary response under
in vitro assay conditions is unlikely, these H. pylori-specific
responses may represent T cells educated on cross-reactive
antigens from commensals or other pathogens. A deeper
understanding of these heterologous immune responses may shed
light on how some H. pylori naı¨ve persons are protected from
disorders associated with the absence of H. pylori.
Recently, a model relating how H. pylori infection stimulates
antigen presenting cells to program CD4+ T cells has emerged
from mouse studies [33]. It proposes that H. pylori drive gastric
dendritic cells (DCs) to become tolerogenic. These DCs migrate to
mesenteric lymph nodes where they encounter naı¨ve T cells and
convert them to Tregs, while poorly inducing Th1 and Th17 cells
[34]. Relative amounts of IL-18 and IL-1b in the DC/T cell
microenvironment determine whether Treg/Th1 or Th17 cells
are preferentially induced. We observed increased Th1 and Treg
signature cytokine production (TNF-a and IL-10) in H. pylori-
infected subjects in multiplex cytokine assays of peptide-stimulated
in vitro PBMC cultures. Th1 cytokine stimulating sequences also
elicit immunosuppressive cytokine production. These results
underscore the complexities of H. pylori-stimulated T cell
responses. While the phenotype of the cell that secretes IL-10
Human Immune Response to H. pylori Epitopes
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has not yet been determined, the result is consistent with human
studies that uncovered gastric Treg-produced IL-10 in H. pylori
infection [35]. Whatever the phenotype, these results provide a
unique opportunity to begin to relate specific H. pylori-derived
sequences to extragastric immunity that is believed to be responsible
for the growing list of benefits of early childhood H. pylori infection.
It is also thought that weak TLR signaling in infection results in
a lack of IL-1b production, which is needed to drive Th17
differentiation [36–39]. H. pylori LPS and flagellin are poor activators
of their respective TLRs 4 and 5, in comparison with their
counterparts in other gram negative bacteria [40,41,42]. Moreover,
while H. pylori bears TLR2 ligands, they stimulate largely anti-
inflammatory responses in vivo [43]. As a result, IL-1b levels are more
limiting than IL-18, so that IL-18 dominates and Th17 differentiation
stalls. As a measure of Th17 stimulation, we measured IL-17A elicited
by epitope peptides and found that levels were not elevated in T cells
from H. pylori-infected relative to uninfected patients. However, the
time course of IL17 secretion is usually delayed compared with other
T-cell dependent cytokines after antigen stimulation [44], which may
partly explain the lack of difference at the single, 24-hour timepoint
that we measured. Additionally, the RPMI medium that we used in
the ELISpot assay is not optimal for Th17 polarization since it has
relatively low levels of the aromatic amino acids necessary for
activation of the aryl hydrocarbon receptor, unlike Iscove’s modified
Dulbecco’s medium, for example. [45] Nonetheless, we note that
both IL-6 and TGF-b1, which are critical for Th17 differentiation
[46], are elevated in H. pylori-infected subjects.
The development of a preventive or therapeutic vaccine against
H. pylori continues to be elusive [47,48]. An H. pylori vaccine is
recognized to be especially valuable for resource-poor countries
with a high burden of H. pylori-related disease, especially as
antibiotic-resistant strains are becoming more prevalent globally
[49,50]. On the other hand, a putative beneficial effect of H. pylori
on asthma and possibly other allergic and inflammatory conditions
outside the stomach in fully industrialized nations demonstrates
the need to better understand the complex interactions of H. pylori
with the human immune system when developing vaccines or
other H. pylori immunotherapeutics. The epitopes identified in this
study may serve as tools to characterize H. pylori-specific T cells
involved in cross-suppression of allergy or chronic inflammation or
activation of inflammatory T cells in humans, thereby aiding the
development of novel immunotherapy and vaccine strategies,
respectively, against this persistent and ubiquitous gastric bacte-
rium. The phenotypes, frequencies and avidities of these distinct T
cells are properties that may influence beneficial or detrimental
responses to subsequent antigenic stimulation in vivo and are
therefore important to further characterize in future studies.
Materials and Methods
Ethics statement
Informed written consent for the study was obtained from all
patients before they underwent endoscopy under a protocol
approved by Rhode Island Hospital’s Institutional Review Board
Figure 3. Comparison of T cell epitope predictions and cytokine responses to 90 individual H. pylori genome-derived peptides. Per
subject and per peptide, the predictive accuracy of IFN-c ELISpot assay responses (N = 15 per cohort) and TNF-a and IL-10 CBA assay responses (N = 5
per cohort) was determined according to subject HLA type, as described in the Methods and Results. Stacked bars illustrate the proportions of true
and false positive predictions and true and false negative predictions per cohort and per cytokine.
doi:10.1371/journal.pone.0094974.g003
Human Immune Response to H. pylori Epitopes
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and in accordance with the principles expressed in the Declaration
of Helsinki. No children were recruited into the study.
Subjects and H. pylori determination
Subjects were recruited for the present study from patients age
$18 years undergoing esophagogastroscopy at Rhode Island
Hospital. Exclusion criteria were active gastrointestinal bleeding,
anemia, pregnancy, previous gastric surgery, use of nonsteroidal
anti-inflammatory drugs (NSAIDs), anticoagulant drugs, proton
pump inhibitors (PPI), histamine (H2)-receptor antagonists,
bismuth compounds or antibiotics within the previous 1 month,
and endoscopic findings of malignant or bleeding lesions. H. pylori
status was ascertained by histology (hematoxylin and eosin
staining), immunohistochemistry and rapid urease testing of
gastric biopsies.
A total of 15 H. pylori-infected and 15 H. pylori-uninfected
patients were recruited. Their average age was 4862.9 years. 53.3
% were male, 16.7% were Asian, 40.0% were Hispanic or Latino
and 43.3 % were white. There were no significant differences
between the groups for age, gender or racial/ethnic distributions.
Peripheral blood mononuclear cells (PBMCs) extraction
Approximately 60 ml of peripheral venous blood was obtained
by venipuncture from each subject and PBMCs harvested using
lympholyte H (Cedarlane Laboratories USA Inc., Burlington, NC)
as the density gradient according to the manufacturer’s instruc-
tions. After washing with PBS, PBMCs were resuspended in RPMI
1640 supplemented with 10% heat inactivated human AB serum
(Valley Biomedical Products & Services, Inc. Winchester, VA),
100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-
glutamine (Lonza, Hopkinton, MA). Viable cells were counted by
trypan blue exclusion, and 2.56105 cells per well were immedi-
ately plated for ELISpot assays with the peptide panel. Approx-
imately 56106 PBMCs per subject were stored at 280uC for HLA
typing.
Epitope selection and peptide synthesis
The top-scoring 90 H. pylori consensus sequences, according to
predictive epitope mapping using the EpiMatrix algorithm and in
vitro HLA binding assays [15], were synthesized as 15,25 mer
peptides (mean length 19-mer). Synthetic peptides were manufac-
tured using 9-fluoronylmethoxycarbonyl (Fmoc) chemistry by 21st
Century Biochemicals (Marlboro, MA). Peptide purity was .80%
as ascertained by analytical reversed phase HPLC. Peptide mass
was confirmed by tandem mass spectrometry. Individual peptides
were dissolved in sterile dimethyl sulfoxide (DMSO) and used at a
final concentration of 10 mg/ml. Table S1 lists the identity of the
peptide sequences that we tested and their corresponding proteins
using the nomenclature of H. pylori reference strain 26695, from
which the sequences were derived, as described previously [15].
Enzyme-linked immunosorbent spot (ELISpot) assay
Freshly extracted PBMCs were pipetted at 2.56105/well into
96-well multiscreen HTS filter plates (EMD Millipore, Billerica,
MA) for human IFN-c ELISpot assay (eBioscience Inc., San
Diego, CA). Each well was stimulated for 24 hours with 10 mg/ml
of a single peptide. Triplicate controls per subject were: DMSO
0.05% as the negative control and 20 ng/ml Phorbol 12-myristate
13-acetate (PMA) with 1 mM ionomycin (Sigma-Aldrich, St.
Louis, MO) as the positive control. Inhibition of peptide-
stimulated IFN-c production was performed on frozen PBMCs
in the presence or absence of anti-HLA DP, DR, DQ antibody
(Clone: Tu39, BD Biosciences). IFN-c spot forming cells (SFC)
were counted by an S5 automated immunospot analyzer (Cellular
Technology Limited, Shaker Heights, OH). Average IFN-c
responses to each peptide were calculated after subtraction of
two times the background IFN-c immunospots obtained from the
mean of the negative control wells. Peptide elicited IFN-c
responses were expressed as spot forming cells (SFC) /million
PBMCs.
Characterization of the secreted cytokine profile
Twenty-four hour PBMC supernatants from each ELISpot well
were collected from five H. pylori-infected and five H. pylori
uninfected subjects and assayed for TNF-a, IL-10, IL-6, IL-4, IL-2
and IL-17A using the human Th1/Th2/Th17A CBA assay kit
(BD Biosciences, San Jose, California) on an LSR II flow
cytometer (BD Biosciences). From these same 24-hour PBMC
supernatants TGF-b1 was measured by an ELISA (eBioscience,
San Diego, CA) that has a detection range of 8 to 1000 pg/ml.
Human leukocyte antigen (HLA) typing
Donor HLA Class II types were determined using the Micro
SSPTM High Resolution HLA Class II kit (One Lambda, Canoga
Park, CA) at the Hartford Hospital Transplant Immunology
Laboratory.
Statistical analysis of immunoassay data
All statistical evaluation was performed with GraphPad Prism
version 5.01 (GraphPad, La Jolla, CA). The SFC comparison and
difference of cytokine expression between the two groups (H. pylori
positive versus negative) was done by unpaired student t test with
Welch’s correction. The correlation between SFC and TNF-a
expression was evaluated by Pearson correlation coefficient. P
values of ,0.05 were considered to be statistically significant.
Immunoinformatic analysis
Per subject and per predicted epitope sequence, individual T
cell epitope measure (iTEM) scores were calculated by summing
top 5th percentile EpiMatrix Z-scores (hits) according to subject
HLA type over both DR alleles [21]. For sequences containing
multiple hits, per allele, scores in descending magnitude were
weighted by a multiple of 1/x for ‘x’ number of hits.
Per subject, iTEM scores for the set of 90 peptides were
correlated with ELISpot and CBA assay data for each cytokine.
The minimal iTEM score that positively correlates with cytokine
data with statistical significance (p,0.05) by the Chi-squared test
for the H. pylori-infected cohort across all epitopes tested was
calculated. To determine this value, iTEM score and cytokine data
pairs were classified as true or false positives or true or false
negatives. True positives are peptide-HLA pairs with both positive
iTEM scores and cytokine values. True negatives are peptide-
HLA pairs with both negative iTEM scores and cytokine values.
False positives have positive iTEM scores and negative cytokine
values, and false negatives, have negative iTEM scores and
positive cytokine values. For cytokine data, the cutoff for positivity
was positive values greater than twice background levels in the
ELISpot assay and positive values after background subtraction in
the CBA assay. The iTEM value determined for the H. pylori-
infected cohort was applied to the H. pylori-negative dataset for
comparison of the true and false positives and true and false
negatives of the two groups.
Supporting Information
Table S1 H. pylori peptides used in PBMC studies.
PEPTIDE ID refers to a four-digit identifier for each peptide.
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26695 ACCESSION NUMBER refers to the GenBank accession
number source of the initial 9-mer ‘‘seed’’ for each predicted H.
pylori Class II peptide. SEQUENCE refers to the amino acid
sequence of the given peptide. SOURCE PROTEIN refers to the
protein description from which each predicted epitope is derived.
(XLSX)
Table S2 IFN-c ELISpot results listed by subject and
peptide. HLA types are listed as shown below each subject’s
designation. All values for peptide responses are the number of
spot forming cells per million after subtraction of two times the
background values obtained from the mean of the negative control
wells.
(XLSX)
Table S3 Cytokine bead array and TGF-b1 results listed
by subject and peptide. Each tab of the spreadsheet opens a
data sheet for an individual cytokine. HLA types are listed as
shown below each subject’s designation. Subject identity numbers
correspond to the subjects listed in Table S2.
(XLSX)
Table S4 Accuracy of predicted cytokine responses
listed by subject and peptide. Each tab of the spreadsheet
opens a data sheet for an individual cytokine. Subject identity
numbers correspond to the subjects listed in Table S2. HpN = H
pylori negative subject; HpP = H pylori positive subject. PEPTIDE
NAME refers to a four-digit identifier for each peptide. PEPTIDE
SEQUENCE refers to the amino acid sequence of the given
peptide. TEST OUTCOME refers to the spot number or cytokine
concentration measured by ELISpot or CBA assay, respectively.
Values above zero are defined as positive responses, as described
in the Methods and Results. ALLELE 1/ALLELE 2 EPIMA-
TRIX MAX SCORE refers to the EpiMatrix Z-score of the
highest scoring 9-mer sequence of a peptide. Cutoff for positivity is
Z-score $1.64 (top 5th percentile). EPIMATRIX PREDICTION
STATUS refers to predictive accuracy of cytokine response in
relation to both EpiMatrix max scores (true or false positive, true
or false negative). ITEM SCORE refers to the iTEM score
calculated for the combined HLA class II alleles of the subject for a
given peptide. Cutoffs for positivity (described in Results): IFN-c
ELISpot: 5.02; TNF-a CBA: 5.1; IL-10 CBA: 5.36; IL-2: 2.4; IL-
4: 8.71; IL-6: 5.0; IL-17A: 7.5. ITEM PREDICTION STATUS
refers to predictive accuracy of cytokine response in relation to
iTEM score (true or false positive, true or false negative).
(XLSX)
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